Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al.

Gualtierotti R, Ingegnoli F, Meroni PL.

Clin Rheumatol. 2013 May;32(5):727-8. doi: 10.1007/s10067-013-2241-3. Epub 2013 May 2. No abstract available.

PMID:
23636791
2.

Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases.

Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, Ternant D, Ardizzone M.

Clin Rheumatol. 2013 May;32(5):695-700. doi: 10.1007/s10067-012-2156-4. Epub 2013 Jan 5.

PMID:
23292481
3.

Treatment with biologics of pregnant patients with rheumatic diseases.

Ostensen M, Förger F.

Curr Opin Rheumatol. 2011 May;23(3):293-8. doi: 10.1097/BOR.0b013e328344a732. Review.

PMID:
21346578
4.
5.

Fetal outcomes after rituximab exposure in women with autoimmune vasculitis.

Pendergraft WF 3rd, McGrath MM, Murphy AP, Murphy P, Laliberte KA, Greene MF, Niles JL.

Ann Rheum Dis. 2013 Dec;72(12):2051-3. doi: 10.1136/annrheumdis-2013-203833. Epub 2013 Jul 17. No abstract available.

6.

Pregnancy outcomes after maternal exposure to rituximab.

Chakravarty EF, Murray ER, Kelman A, Farmer P.

Blood. 2011 Feb 3;117(5):1499-506. doi: 10.1182/blood-2010-07-295444. Epub 2010 Nov 23.

7.

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.

Johnston SS, Turpcu A, Shi N, Fowler R, Chu BC, Alexander K.

Semin Arthritis Rheum. 2013 Aug;43(1):39-47. doi: 10.1016/j.semarthrit.2012.12.024. Epub 2013 Feb 27.

PMID:
23453683
8.

Rituximab for autoimmune blistering diseases: recent studies, new insights.

Lunardon L, Payne AS.

G Ital Dermatol Venereol. 2012 Jun;147(3):269-76.

9.

Safety issues of biologics in pregnant patients with rheumatic diseases.

Ostensen M.

Ann N Y Acad Sci. 2014 May;1317:32-8. doi: 10.1111/nyas.12456. Epub 2014 May 19.

PMID:
24840548
10.

Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?

Malmström V, Trollmo C, Klareskog L.

Arthritis Res Ther. 2005;7 Suppl 2:S15-20. Epub 2005 Mar 16. Review.

11.

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.

Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ.

Rheumatology (Oxford). 2011 Dec;50(12):2297-305. doi: 10.1093/rheumatology/ker289. Epub 2011 Oct 22. Review.

PMID:
22019799
12.

Management of RA medications in pregnant patients.

Østensen M, Förger F.

Nat Rev Rheumatol. 2009 Jul;5(7):382-90. doi: 10.1038/nrrheum.2009.103. Epub 2009 Jun 9. Review.

PMID:
19506586
13.

An antibody treats almost all refractory autoimmune diseases: fact and beyond.

Lin LY, Hsu MH, Yang KD.

J Formos Med Assoc. 2012 Apr;111(4):181-2. doi: 10.1016/j.jfma.2011.05.004. No abstract available.

PMID:
22655322
14.

[Perspectives in clinical immunology].

Rolla G, Ferrero N, Bergia R, Guida G.

Recenti Prog Med. 2006 Dec;97(12):787-96. Review. Italian.

PMID:
17252738
15.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. No abstract available. Erratum in: Ann Rheum Dis. 2009 Mar;68(3):452. Kavanaugh, A [added].

PMID:
19022808
16.

Rituximab and its use in autoimmune bullous disorders.

Daniel BS, Murrell DF, Joly P.

Immunol Allergy Clin North Am. 2012 May;32(2):331-7, viii. doi: 10.1016/j.iac.2012.04.013. Epub 2012 Apr 18.

PMID:
22560146
17.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME.

Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii2-22. Review. No abstract available. Erratum in: Ann Rheum Dis. 2008 Feb;67(2):280.

18.

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.

Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P.

Arthritis Res Ther. 2013 Oct 30;15(5):R171. doi: 10.1186/ar4358.

19.

Rituximab and its use in autoimmune bullous disorders.

Daniel BS, Murrell DF, Joly P.

Dermatol Clin. 2011 Oct;29(4):571-5. doi: 10.1016/j.det.2011.06.023.

PMID:
21925000
20.

The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.

Siddiqui MA.

Curr Opin Rheumatol. 2007 May;19(3):308-13. Review.

PMID:
17414961

Supplemental Content

Support Center